Skip to main content
. 2024 Jan 26;5(2):101393. doi: 10.1016/j.xcrm.2024.101393

Figure 4.

Figure 4

Atezolizumab added to GemCis versus GemCarbo leads to distinct transcriptional states of circulating immune cells including changes reflective of T cell activation states

(A) UMAP visualization of total T and NK cells captured, colored by major cell types (n = 707,614).

(B) UMAP visualization of total CD8 T cells captured, colored by different cell types (n = 171,729) (left), and heatmap showing scaled expression of the top 10 cell markers ranked by fold change in each cell type (right). Black asterisks indicate cell types not included in subsequent analysis due to low cell numbers.

(C) Heatmaps showing pathway enrichment on-treatment (C3D1) versus at baseline (C1D1) across T and NK cell types. Treatments received were GemCis (first panel, n = 17 pairs) or GemCarbo (second panel, n = 16 pairs) in arm C and GemCis + atezolizumab (third panel, n = 14 pairs) or GemCarbo + atezolizumab (fourth panel, n = 24 pairs) in arm A.

(D) Heatmaps showing pathway enrichment with GemCis on-treatment (C3D1) versus baseline (C1D1) across T and NK cell types in responders (left) and nonresponders (right). In (C) and (D), red indicates enrichment in on-treatment samples and blue indicates enrichment at baseline. The hue represents the false discovery rate (FDR) significance derived from the fgsea package. Black asterisks represent FDR < 0.05.